The market may have dropped lower this morning, but that hasn’t stopped the MGC Pharmaceuticals Ltd (ASX: MXC) share price from pushing notably higher.
At one stage the cannabis company’s shares were up 19% at an all-time high of 12.5 cents before fading slightly. At the time of writing its shares are 9.5% higher to 11.5 cents.
Why are MGC Pharmaceuticals’ shares surging higher today?
This morning MGC Pharmaceuticals made an announcement relating to its European medicinal cannabis manufacturing facility.
According to the release, the company has been formally granted interim Good Manufacturing Practice (GMP) certification for the facility.
The interim certification means the company can commence production of the first batch of its adult medical cannabis epilepsy product CannEpil.
Upon successful production of the first batch of CannEpil, the batch will undergo validation of manufacturing and analysis. After which, if the product meets the required protocols, management expects the facility will be granted full GMP certification.
This will then allow MXC Pharmaceuticals to commence full scale manufacture and be licensed for distribution of CannEpil and other pharmaceutical grade medicinal cannabis products.
What is CannEpil?
CannEpil is the company’s first pharmaceutical-grade medical cannabis product and is targeting drug-resistant epilepsy. Drug-resistant epilepsy, also known as refractory epilepsy, is a potentially lucrative market and accounts for approximately 30% of the estimated 240,000 people diagnosed with epilepsy in Australia each year.
Management estimates that the product will generate revenue of $1 million per annum from its first full year of distribution with specialist Australian pharmaceutical distributor HL Pharma.
Should you invest?
I’ve been impressed with MXC Pharmaceuticals over the last few months and believe it has shown a lot of promise. As well as this product, the company has signed a number of agreements in the cosmetic industry that have the potential to generate meaningful revenues.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- Why Kathmandu, Resolute, Select Harvests, & Treasury Wine Estates are dropping lower – November 30, 2020 12:48pm
- ASX 200 drops 0.5%: Treasury Wine sinks, Zip flat after AGM update, Bega Cheese rises – November 30, 2020 12:07pm
- Why Afterpay, Bega Cheese, Humm, & Telix shares are storming higher – November 30, 2020 11:37am